Radiation boosts immunotherapy in lung cancer trial
NCT ID NCT06121505
First seen Jan 04, 2026 · Last updated Jun 21, 2026 · Updated 26 times
Summary
This phase 2 trial tests whether adding low-dose radiation to standard immunotherapy (sintilimab) and chemotherapy can shrink tumors better than immunotherapy and chemo alone in people with advanced squamous cell lung cancer. About 114 participants will be randomly assigned to one of two groups. The study is currently recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG SQUAMOUS CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Hospital of North Sichuan Medical College
RECRUITINGNanchong, Sichuan, 637503, China
Contact Email: •••••@•••••
-
Guizhou Provincial People's Hospital
RECRUITINGGuiyang, Guizhou, 550002, China
Contact Email: •••••@•••••
-
Sichuan Cancer Hospital
RECRUITINGChengdu, Sichuan, 610044, China
Contact Email: •••••@•••••
-
The Second Affiliated Hospital of Chongqing Medical University
RECRUITINGChongqing, Chongqing Municipality, 400010, China
Contact Email: •••••@•••••
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hunan, 430022, China
Contact Email: •••••@•••••
-
West China Hospital of Sichuan University
RECRUITINGChengdu, Sichuan, 610044, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sintilimab (PD-1 inhibitor) plus chemotherapy, with low-dose radiation therapy and stereotactic body radiation therapy
What this could lead to
If it works, this could offer a more effective first-line treatment for advanced squamous cell lung cancer by combining radiation with immunotherapy and chemo.
What could go wrong
This is a small, early-phase (Phase 2) trial with only 114 participants. Adding radiation may increase side effects, and the benefit over standard treatment is not yet proven.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.